Optimal Treatment Interval of Viscosupplementation for Osteoarthritic Knee Pain: Real-world Evidence from a Retrospective Study
Janice Johnston1, Jeffrey Muir2, *, Michael J. Sloniewsky3
Identifiers and Pagination:Year: 2022
E-location ID: e187432502212020
Publisher ID: e187432502212020
Article History:Received Date: 28/12/2022
Revision Received Date: 25/10/2022
Acceptance Date: 2/11/2022
Electronic publication date: 29/12/2022
Collection year: 2022
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The evidence supporting multiple courses of viscosupplementation for knee osteoarthritis continues to grow; however, the optimal treatment interval for repeat courses is not well understood. To address this, we compared baseline pain and disability scores in patients returning for subsequent treatment with their prior discharge scores.
We retrospectively collected data from patients at 16 rehabilitation clinics who presented for repeated courses of viscosupplementation treatment for knee OA. Primary outcomes were pain (visual analog scale, VAS) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores, which were collected following the initial treatment course and compared with scores upon return for treatment. The proportion of patients who fulfilled a minimal clinically important difference in each outcome was calculated.
61 patients (81 knees) were included in our analysis. After a 6-month treatment interval, no significant differences were noted between post-discharge and returning scores for either VAS (p=0.73) or WOMAC (Pain: p=0.42; Function: p=0.54; Stiffness: p=0.29). Patients waiting 9 months to return for treatment saw a 45% increase in their pain scores (p=0.10) and significant worsening in WOMAC scores (Pain: p=0.007; Function: p=0.03; Stiffness: p=0.04). At 12 months, pain (p=0.01), WOMAC Pain (p=0.05), and WOMAC Stiffness (p=0.02) had all worsened significantly compared to discharge following the initial course.
Our data indicate that patients who return for treatment within a 6-month treatment interval maintain their improvements, but that when the interval increases to 9 months or more, patients present as significantly worsened, having lost the benefit of their initial course of treatment.